Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial

Not Applicable

Completed

• Conditions: Intestinal Dysplasia; Colorectal Neoplasms; Barrett's Esophagus; Esophageal Dysplasia
• Interventions: Device: Nestis® jet injector system with a bi-functional catheter

• Registration Number: NCT01913223
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

ESD (Endoscopic Sub-mucosal Dissection)is the first-intent method to treat superficial neoplasms of the digestive tract at it allows an en-bloc R0 resection. Following marking of the lesion margins, ESD comprises 3 steps: 1) liquid injection into the sub-mucosal space 2) circumferential (complete or partial) incision and 3) dissection of the submucosa. Several tools are necessary to perform ESD with the standard technique. Development of water jet with bi functional (injection and cutting) catheter allows time and significant reduction of perforation risk (due to multiple changes of instruments). For this purpose, Nestis introduced the Enki 2 pulsed jet technology with high pressure system to inject efficiently and at any time viscous solutions in direct viewing and retroflexion. Preliminary pig studies indicate that injection of glycerol, hyaluronate and hydroxyethlstarch with Enki 2 are possible. In addition, preclinical studies on living pig colon models using saline solutions have demonstrated that perforation rates and operating times are significantly reduced compared to a standard electrosurgical knife. The present clinical study is being performed to confirm this system capability to perform ESD in humans.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2013-07-30
• Study First Submitted QC: 2013-07-31
• Study First Posted: 2013-08-01
• Primary Completion: 2013-12
• Study Completion: 2014-07
• Status Verified: 2014-08
• Last Update Submitted: 2019-05-23
• Last Update Posted: 2019-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• in the esophagus: squamous cell carcinoma (well differentiated G1) or high grade dysplasia or neoplasia on barrett esophagus with high grade dysplasia or adenocarcinoma confirmed by two different pathologists, with only superficial tissue (mucosal invasion (T1m) and no lymph nodes on EUS endoscopy radial and mini probe), larger than 15 mm of diameter, with an extension of less than 10 cm high and less than two thirds of the esophageal circumference
• in the stomach: superficial adenocarcinoma or high grade dysplasia (well differentiated G1) with no depth invasion of the sub mucosa in EUS endoscopy and no lymph nodes according to the recommendations of the Japanese gastric cancer association, and with a diameter of more than 15 mm
• in the colon and the rectum: sessile serrated adenomas, adenomas or superficial adenocarcinoma (well differentiated G1), larger than 15 mm, corresponding to non granular Lateral spreading tumor (NG-LST) or granular (G-LST) with a focal Kudo V zone in the lesion, with a circumferential extension of less than two thirds and with only a superficial extension (no sub mucosal invasion and no lymph nodes in EUS endoscopy of the rectum).
• Consent form signed
• Anesthesiology risk limited with ASA score 1 or 2
• Patients over 18 years old
• Affiliation to social safety system

Exclusion Criteria

• other lesions of the digestive tract
• high anesthetic risk (ASA score > 2)
• previous treatment of the lesion (radiotherapy, endoscopy, surgery, chemotherapy...)
• other malignant disease locally advanced or with metastasis
• hemostasis disorders
• pregnancy or breast feeding
• participation in another clinical trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
submucosal dissection by dissector water jet	Nestis® jet injector system with a bi-functional catheter	-

Primary Outcome Measures

Name	Time	Method
Safety outcome	At 1 month	Safety is measured in term of perforation rate and bleeding rate with immediate complication or delayed one after the procedure, at one month complications are not linked to the ESD procedure

Secondary Outcome Measures

Name	Time	Method
Effectiveness of the procedure in terms of complete neoplasia resections	three month	no macroscopic nor microscopic local recurrence during follow up endoscopy

Trial Locations

Locations (1)

Hôpital Edouard Herriot; 🇫🇷 Lyon, France